

**Table 1** : Baseline characteristics of the 609 patients included in the APROCO-COPILOTE genetic sub-study according to CCR5 genotype

Characteristics		wt/wt (n=512)	$\Delta$ 32/wt (n=97)	p
Male gender	N (%)	409 (80)	79 (81)	0.72
Age (years)	median (IQR)	37 (32-43)	38 (33-46)	0.05
Primary risks for HIV infection	N (%)			0.03
Injection drug use		87 (17)	8 (8)	
Place of birth	N(%)			0.0020
Europe		366 (71)	85 (88)	
Africa		68 (13)	3 (3)	
Other		24 (5)	-	
Missing data		54 (11)	9 (9)	
Year of first HAART	N (%)			0.68
1997		247 (48)	49 (51)	
1998-1999		265 (52)	48 (49)	
AIDS stage	N (%)	114 (22)	20 (21)	0.72
CD4+ cell count (/mm <sup>3</sup> )	median (IQR)	265 (119-403)	321 (156-466)	0.06
HIV-RNA (log <sub>10</sub> copies/ml)	median (IQR)	4.5 (3.7-5.2)	4.3 (3.6-4.7)	0.02
No prior antiretroviral treatment	N (%)	226 (44)	43 (44)	0.97

**Table 2:** Factors associated with stable long-term virological response\* in 609 patients included in the APROCO-COPILOTE cohort assessed for CCR5  $\Delta$ 32 deletion

Variables	Month 4 to year 3							Month 4 to year 5						
	Univariable analysis			p	Multivariable analysis			p	Univariable analysis			Multivariable analysis		
	% success	OR	95% CI		OR	95% CI	% success		OR	95% CI	OR	95% CI	p	
CCR5 deletion				0.02			0.09				0.01			0.04
$\Delta$ 32/wt	65	1.74	1.10-2.75		1.59	0.93-2.73		48	1.77	1.12-2.78		1.77	1.03-3.04	
wt/wt	52	1			1			35	1			1		
Sex				0.44			0.89							0.22
Male	55	1			1			37	1			1		
Female	51	0.85	0.57-1.28		1.04	0.61-1.76		35	0.91	0.59-1.40		1.42	0.81-2.48	
Age (years)				0.23			0.91							0.33
<37	52	1			1			31	1			1		
$\geq$ 37	57	1.22	0.88-1.68		0.98	0.67-1.44		43	1.69	1.19-2.38		1.22	0.82-1.83	
Origin of birth				0.07			0.14							0.12
Africa	45	0.63	0.38-1.04		0.65	0.36-1.16		29	0.64	0.36-1.14		0.61	0.32-1.14	
Other	57	1			1			39	1			1		
Contamination group				0.58			0.69							0.27
Homo/bisexual	56	1.10	0.79-1.52		0.92	0.60-1.41		40	1.29	0.91-1.82		1.29	0.82-2.01	
Other	54	1			1			34	1			1		
HIV-RNA at baseline (log <sub>10</sub> copies/ml)				0.17			0.09							0.56
<3,7	62	1			1			38	1			1		
[3,7 ; 4,5[	49	0.60	0.38-0.94		0.57	0.34-0.98		31	0.72	0.44-1.17		0.68	0.39-1.20	
[4,5 ; 5,2[	55	0.77	0.49-1.21		0.60	0.33-1.07		39	1.02	0.64-1.63		0.84	0.45-1.56	
$\geq$ 5,2	53	0.71	0.44-1.13		0.45	0.23-0.87		41	1.12	0.69-1.81		0.71	0.35-1.41	

CD4 /mm <sup>3</sup> at baseline				0.002		0.004				0.04			0.06
<200	52	0.46	0.27-0.78		0.36	0.19-0.69		39	0.77	0.45-1.29		0.52	0.27-1.00
[350-500[	46	0.36	0.20-0.62		0.33	0.17-0.62		28	0.46	0.26-0.81		0.40	0.21-0.79
[200-350[	59	0.61	0.34-1.10		0.51	0.26-1.01		38	0.72	0.41-1.27		0.54	0.27-1.06
≥500	71	1			1			46	1			1	
Time spent on cART** (months)				<0.0001		<0.0001					-		-
>35	62	3.70	2.47-5.52		3.57	2.24-5.69		-	-		-		-
≤35	31	1			1								
Time spent on cART** (months)				-	-						<0.0001		<0.0001
>55	-	-	-	-	-			44	5.91	3.34-10.46		6.15	3.28-11.53
≤55								12	1			1	
Adherence				0.001		0.02					0.0011		0.02
non adherence	30	0.27	0.12- 0.62		0.25	0.09-0.68		14	0.20	0.06-0.61		0.28	0.08-0.94
low adherence	42	0.44	0.26-0.75		0.54	0.30-0.99		24	0.39	0.22-0.71		0.41	0.21-0.80
moderate adherence	56	0.78	0.54-1.13		0.84	0.55-1.30		36	0.70	0.48-1.02		0.68	0.44-1.04
high adherence	67	1			1			50	1			1	
Prior antiretroviral treatment				0.0003		<0.0001					0.0001		0.002
yes	63	1.84	1.32-2.55		2.98	1.85-4.79		46	1.95	1.38-2.75		2.18	1.33-3.55
no	48	1			1			30	1			1	

\* stable virological response defined as plasma HIV-1 RNA measurement below the threshold of detection of 500 copies/ml at all measurements except once between M4 and year 3 and 5.

\*\*cART: combination antiretroviral treatment